コンテンツへスキップ
Merck

M-083

Supelco

メチルフェニデート 塩酸塩 溶液

(Racemic mixture), ampule of 1 mL, 1.0 mg/mL in methanol (as free base), certified reference material, Cerilliant®

ログイン組織・契約価格を表示する


About This Item

実験式(ヒル表記法):
C14H20ClNO2
CAS番号:
分子量:
269.77
MDL番号:
UNSPSCコード:
41116107
PubChem Substance ID:
NACRES:
NA.24

グレード

certified reference material

品質水準

フォーム

liquid

特徴

Snap-N-Spike®/Snap-N-Shoot®

包装

ampule of 1 mL

メーカー/製品名

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IIB (Portugal)

濃度

1.0 mg/mL in methanol (as free base)

テクニック

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

アプリケーション

forensics and toxicology

フォーマット

single component solution

保管温度

2-8°C

SMILES記法

Cl.COC(=O)C(C1CCCCN1)c2ccccc2

InChI

1S/C14H19NO2.ClH/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12;/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3;1H

InChI Key

JUMYIBMBTDDLNG-UHFFFAOYSA-N

遺伝子情報

詳細

Methylphenidate is a psychostimulant prescribed for treatment of attention-deficit hyperactivity disorder (ADHD), tachycardia and narcolepsy. This Certified Spiking Solution® is applicable for use in LC/MS or GC/MS applications for urine drug testing, clinical toxicology and forensic analysis. Methylphenidate is sold under trade names Concerta® and Ritalin®.

アプリケーション


  • Methylphenidate HCl solution in ADHD pharmacotherapy studies: Research published in "Molecular Psychiatry" explored the effects of methylphenidate on Drosophila brain at single-cell resolution, highlighting its potential for ADHD treatment repurposing and its impact on neurotransmitter regulation (Qu et al., 2023).

  • CNS stimulant research with high-purity methylphenidate HCl: A case study in "Children (Basel)" detailed the complex relationship between ADHD symptoms and self-induced weight loss in a child, underscoring methylphenidate′s role in managing hyperkinetic disorders and its potential interactions with eating behaviors (Mestermann et al., 2023).

  • Neuropharmacology Methylphenidate in neurotransmitter research: A review in "Molecular Biotechnology" discussed the pharmacological applications of amino acids, using methodologies that could be applied to substances like methylphenidate for enhanced understanding of its interaction with brain chemistry and neurotransmitter functions (Kamaraj and Vuppu, 2023).

  • Liquid methylphenidate for in vitro neuropharmacology studies: An analysis in "Journal of Medical Internet Research" investigated the nonmedical use and adverse effects of methylphenidate, providing insights into its impact during the COVID-19 pandemic and highlighting the importance of monitoring drug usage trends for improved public health strategies (Shin et al., 2023).

  • Dopamine reuptake inhibitor research with methylphenidate solution: A report in "Journal of Analytical Toxicology" detailed a case of fatal intoxication where methylphenidate′s properties as a dopamine reuptake inhibitor were considered in the context of its toxicological profile, emphasizing the need for careful monitoring of its use and effects (Ameline et al., 2023).

法的情報

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Concerta is a registered trademark of ALZA Corporation
Ritalin is a registered trademark of Novartis Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

ピクトグラム

FlameSkull and crossbonesHealth hazard

シグナルワード

Danger

危険有害性情報

危険有害性の分類

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

ターゲットの組織

Eyes,Central nervous system

保管分類コード

3 - Flammable liquids

WGK

WGK 2

引火点(°F)

49.5 °F - closed cup

引火点(℃)

9.7 °C - closed cup


適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

消防法

第4類:引火性液体
アルコール類
危険等級II

労働安全衛生法名称等を表示すべき危険物及び有害物

名称等を表示すべき危険物及び有害物

労働安全衛生法名称等を通知すべき危険物及び有害物

名称等を通知すべき危険物及び有害物

Jan Code

M-083-1ML:4548173314716
M-083-CC:


最新バージョンのいずれかを選択してください:

試験成績書(COA)

Lot/Batch Number

申し訳ございませんが、現在この製品のCOAをオンラインで入手できません。

サポートが必要な場合は、お問い合わせください カスタマーサポート

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

この製品を見ている人はこちらもチェック

Slide 1 of 2

1 of 2

Eduardo Bruera et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(19), 2421-2427 (2013-05-22)
Cancer-related-fatigue (CRF) is common in advanced cancer. The primary objective of the study was to compare the effects of methylphenidate (MP) with those of placebo (PL) on CRF as measured using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) fatigue
Methylphenidate in the management of cancer-related fatigue.
Patrick C Stone
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(19), 2372-2373 (2013-05-22)
Evert J Semeijn et al.
Journal of the American Geriatrics Society, 61(6), 882-887 (2013-05-29)
To increase insight into the effect of attention-deficit/hyperactivity disorder (ADHD) on health in general in older adults. Two-phase sampling side-study. Longitudinal Aging Study Amsterdam (LASA). Two hundred twenty-three randomly selected LASA respondents. Information was collected during home visits on physical
Methylphenidate: trismus.
Prescrire international, 22(140), 185-185 (2013-08-21)
Methylphenidate vs atomoxetine: personalized medicine in attention- deficit/hyperactivity disorder.
Hartmut Heinrich et al.
JAMA psychiatry, 70(5), 545-545 (2013-05-03)

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)